- Home
- ESQ vs INBX Comparison
ESQ vs INBX Comparison
Compare ESQ & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESQ | INBX |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 999.7M |
| IPO Year | 2017 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ESQ | INBX |
|---|---|---|
| Price | $112.01 | $110.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $120.33 | ★ $150.00 |
| AVG Volume (30 Days) | 81.3K | ★ 601.0K |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $35.15 | N/A |
| Revenue Next Year | $39.09 | N/A |
| P/E Ratio | $77.66 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $87.54 | $12.80 |
| 52 Week High | $119.86 | $155.29 |
Technical Indicators
Market Signals| Indicator | ESQ | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 59.67 | 49.89 |
| Support Level | $104.58 | $69.30 |
| Resistance Level | $115.69 | $153.14 |
| Average True Range (ATR) | 2.50 | 13.62 |
| MACD | 0.48 | -4.06 |
| Stochastic Oscillator | 92.14 | 20.59 |
Price Performance
Historical ComparisonAbout ESQ Esquire Financial Holdings Inc.
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.